QuadMedicine Signs Technology Transfer Agreement for Osteoporosis Treatment with Hallim Pharm

[Asia Economy Reporter Park Jihwan] Medical microneedle platform company ‘Quadmedison’ announced on the 7th that it has signed a technology transfer agreement with Hallim Pharmaceutical for an osteoporosis treatment using microneedles.

This technology transfer agreement includes an upfront payment and milestone royalties for clinical trials, process development, and production facility establishment. Royalties based on sales revenue generated after commercialization will be paid separately. Through this agreement, Quadmedison grants Hallim Pharmaceutical the exclusive worldwide rights to manufacture and sell the microneedle osteoporosis treatment.

Quadmedison is recognized for its cutting-edge technologies such as ‘multi-coated microneedles’ and ‘immediate separation microneedles’ and is jointly developing vaccines and synthetic drugs with several companies. The microneedle osteoporosis treatment technology transferred to Hallim Pharmaceutical this time involves loading drugs onto immediate separation microneedles.

This is the first case of microneedle technology transfer to a domestic pharmaceutical company, with Quadmedison being the only one. Based on medical device and pharmaceutical GMP facilities, Quadmedison has succeeded in microneedle process development and scale-up production, growing into a global leading company in medical microneedle platform technology capable of loading various drugs.

Quadmedison’s medical microneedles consist of numerous micro-needles smaller than 1 millimeter arranged on an area about the size of a fingernail. It is a transdermal drug delivery system (TDDS) technology that delivers active ingredients through the skin by changing the formulation and administration route of existing drugs. Based on its advantages of maximizing user convenience and drug delivery efficiency, many global companies are accelerating the development of microneedle platform technologies. Domestically, Quadmedison is the first to prepare for a phase 1 clinical trial application for a hepatitis B vaccine microneedle.

A Quadmedison official stated, "Starting with this contract, we will expand our business not only with domestic pharmaceutical companies but also with global pharmaceutical companies by utilizing medical microneedle platform technology." Quadmedison has selected NH Investment & Securities as the lead underwriter and is preparing for a KOSDAQ market listing.

This content was produced with the assistance of AI translation services.